GET DAILY SIGNALSWhy Is Picard Medical (PMI) Stock Down -7.78% Today?
Key Takeaways
- PMI shares fell roughly 7.78% intraday on Monday, slipping from a prior close of $9.00 to about $8.30.
- The decline reflects profit-taking and elevated volatility in a thinly traded micro-cap after a sharp multi-day run-up, rather than a single fundamental announcement.
- Ongoing shareholder litigation investigations and lingering concerns around the company's NYSE American listing history continue to weigh on sentiment.
- The move comes as traders position ahead of the company's upcoming quarterly earnings, expected around mid-November.
- Broader healthcare-sector trading was mixed, with PMI's move driven largely by stock-specific dynamics.
- Traders are watching for the earnings release, any clinical or commercialization updates, and whether the stock holds near-term support.
- For more detail on Price Targets, Earnings, and Forecast, explore the dedicated pages for PMI.
- Discover how AI-driven strategies are navigating today's market by exploring Trending AI Robots.
Opening Summary
Picard Medical, Inc. (PMI), the Tucson, Arizona-based medical device company behind the SynCardia Total Artificial Heart, saw its stock pull back sharply on Monday. Shares traded near $8.30 in the session, down about 7.78% from Friday's closing level of $9.00. The move unwound part of the prior session's 14.65% advance and underscored the outsized volatility that has defined this small-cap name, which carries a market capitalization of only about $22 million.
Profit-Taking After a Sharp Rally
The most immediate driver of Monday's decline appears to be profit-taking following a rapid run-up in the shares. PMI has been among the most volatile names in the medical-device space, with large percentage swings in both directions over recent weeks. After a strong advance into the end of last week, short-term traders moved to lock in gains, a pattern that is especially pronounced in micro-cap stocks with limited float and thin liquidity.
Legal and Listing Overhang
Sentiment has also been pressured by a series of shareholder litigation investigations that have accumulated over recent months. Several law firms have announced inquiries into the company on behalf of long-term stockholders, adding an element of uncertainty for investors. Although PMI recently received a compliance-period extension from NYSE American running through November 2027, the company's earlier noncompliance notices and a 1-for-50 reverse stock split remain part of the backdrop that keeps some investors cautious.
Micro-Cap Volatility and Liquidity
As a thinly traded micro-cap, PMI is prone to exaggerated price moves on relatively modest order flow. The company's shares can gain or lose several percentage points in a single session without a corresponding fundamental catalyst. Monday's pullback fits this broader pattern, with the stock giving back a portion of its recent gains amid choppy trading rather than reacting to a specific corporate announcement.
Market Context and Trading Activity
The decline in PMI was largely a stock-specific event rather than a reflection of broad market weakness. Trading was volatile and on relatively thin volume relative to the stock's historical spikes, consistent with a low-liquidity name. The move did not appear to be driven by sector-wide momentum in medical devices, and the company's price action diverged from the steadier tone seen across much of the broader healthcare complex.
What Comes Next for PMI
Looking ahead, investors are focused on the company's upcoming quarterly earnings report, expected around mid-November, which will provide a fresh read on revenue trends from SynCardia Total Artificial Heart utilization and Freedom Driver rentals. Key areas of attention include operating-expense discipline, cash burn, and any updates on the company's next-generation artificial heart pipeline. Risks remain substantial: the company has posted recurring net losses, faces elevated costs, and carries ongoing legal and exchange-compliance uncertainties that could keep volatility high regardless of the broader market's direction.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving users a range of approaches to consider. Explore the Trending AI Robots page to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PMI's RSI Oscillator recovers from overbought zone
The 10-day RSI Indicator for PMI moved out of overbought territory on October 20, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 3 instances where the indicator moved out of the overbought zone. In 3 of the 3 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for PMI turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 7 similar instances when the indicator turned negative. In 7 of the 7 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PMI broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 9 of 11 cases where PMI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on PMI as a result. In 12 of 15 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
PMI moved above its 50-day moving average on November 05, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PMI crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 1 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +25.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where PMI advanced for three days, in 38 of 45 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 6 of 12 cases where PMI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. PMI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.266) is normal, around the industry mean (4.142). P/E Ratio (-0.251) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.114) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement